Last reviewed · How we verify
Japanese Encephalitis purified inactivated vaccine
Japanese Encephalitis purified inactivated vaccine is a Inactivated viral vaccine Biologic drug developed by Valneva Austria GmbH. It is currently in Phase 3 development for Prevention of Japanese encephalitis in at-risk populations and travelers.
This inactivated vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.
This inactivated vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in at-risk populations and travelers.
At a glance
| Generic name | Japanese Encephalitis purified inactivated vaccine |
|---|---|
| Sponsor | Valneva Austria GmbH |
| Drug class | Inactivated viral vaccine |
| Target | Japanese encephalitis virus antigens |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) Japanese encephalitis virus particles that trigger both humoral and cell-mediated immune responses without causing disease. Upon vaccination, the immune system recognizes viral antigens and generates protective antibodies and memory T cells that prevent infection or reduce disease severity upon exposure to live virus.
Approved indications
- Prevention of Japanese encephalitis in at-risk populations and travelers
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fever
Key clinical trials
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. (PHASE1)
- Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 (PHASE3)
- Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 (PHASE3)
- Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 (PHASE3)
- Purified Inactivated Japanese Encephalitis Vaccine (PHASE3)
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population (PHASE3)
- Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries (PHASE3)
- Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Japanese Encephalitis purified inactivated vaccine CI brief — competitive landscape report
- Japanese Encephalitis purified inactivated vaccine updates RSS · CI watch RSS
- Valneva Austria GmbH portfolio CI
Frequently asked questions about Japanese Encephalitis purified inactivated vaccine
What is Japanese Encephalitis purified inactivated vaccine?
How does Japanese Encephalitis purified inactivated vaccine work?
What is Japanese Encephalitis purified inactivated vaccine used for?
Who makes Japanese Encephalitis purified inactivated vaccine?
What drug class is Japanese Encephalitis purified inactivated vaccine in?
What development phase is Japanese Encephalitis purified inactivated vaccine in?
What are the side effects of Japanese Encephalitis purified inactivated vaccine?
What does Japanese Encephalitis purified inactivated vaccine target?
Related
- Drug class: All Inactivated viral vaccine drugs
- Target: All drugs targeting Japanese encephalitis virus antigens
- Manufacturer: Valneva Austria GmbH — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Immunology
- Indication: Drugs for Prevention of Japanese encephalitis in at-risk populations and travelers
- Compare: Japanese Encephalitis purified inactivated vaccine vs similar drugs
- Pricing: Japanese Encephalitis purified inactivated vaccine cost, discount & access